Sinopharm Group's (HKG:1099) profit attributable to owners of the parent fell 1.8% in the first six months of 2026 to 3.40 billion yuan from 3.47 billion yuan a year ago, according to a Monday filing to the Hong Kong stock exchange.
Earnings per share declined to 1.09 yuan from 1.11 yuan a year earlier, the pharmaceutical company said.
Revenue edged down 1.1% to 282.8 billion yuan from 286.04 billion yuan a year ago.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments